Finance
DX-88 and DX-890 maker reports increased net loss
Published in Clinical Trials Week, March 21st, 2005
For the quarter ended December 31, 2004, the company reported a net loss from continuing operations of $9.5 million or $0.31 per share, as compared to a net loss from continuing operations of $7.0 million or $0.28 per share for the comparable quarter of 2003.
For the year ended December 31, 2004, the company reported a net loss from continuing operations of $33.1 million or $1.06 per share, as compared to a net loss from continuing operations of $24.5 million or $1.04 per share for the year ended December 31, 2003. Due to the sale in October 2003 of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2005-03-21)
More Articles from Clinical Trials Week
- Enzymology
Matrix metalloproteinase inhibitor MMI270 helps chemotherapy fight metastasis - Hepatic Encephalopathy
Trial results dispute efficacy of standard management strategies - Non-Hodgkin Lymphoma
Yttrium 90 ibritumomab tiuxetan does not impair subsequent treatment - Pneumococcal Vaccine
Molecular epidemiology of pneumococcal colonization investigated - Vaccine Delivery
Biodegradable microparticles developed for vaccine antigen delivery - Acute Intracerebral Hemorrhage
Journal publishes results of acute intracerebral hemorrhage study - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
